BI
ENGNW icon

BVF Inc’s enGene Therapeutics Warrants ENGNW Stock Holding History

BVF Inc’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.49M Hold
945,402
– – 0.08% 41
2025
Q4 		$2.4M Hold
945,402
– – 0.08% 41
2025
Q3 		$681K Hold
945,402
– – 0.03% 45
2025
Q2 		$586K Hold
945,402
– – 0.02% 43
2025
Q1 		$605K Hold
945,402
– – 0.02% 50
2024
Q4 		$804K Hold
945,402
– – 0.03% 52
2024
Q3 		$804K Hold
945,402
– – 0.02% 52
2024
Q2 		$1.31M Hold
945,402
– – 0.04% 55
2024
Q1 		$4.92M Hold
945,402
– – 0.14% 48
2023
Q4 		$804K Buy
+945,402
New +$727K 0.02% 68

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

BVF Inc's ENGNW Position: Q1 2026 in Review

BVF Inc held its enGene Therapeutics Warrants (ENGNW) position steady in Q1 2026 at 945,402 shares worth $2.49M. The position accounts for 0.08% of the portfolio, ranked #41.

BVF Inc first reported a position in ENGNW in Q4 2023 and has held it in 10 quarters since. The position peaked at $4.92M in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • BVF Inc held 945,402 shares of enGene Therapeutics Warrants worth $2.49M as of Q1 2026.
  • BVF Inc left its enGene Therapeutics Warrants share count unchanged in Q1 2026.
  • enGene Therapeutics Warrants made up 0.08% of BVF Inc's portfolio in Q1 2026, its #41 holding.
  • BVF Inc first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 10 quarters since.
  • BVF Inc's enGene Therapeutics Warrants position peaked at $4.92M in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.